One meal a day is a simple idea with a complicated evidence base. Compressing all food into one sitting can reduce calories because there are fewer chances to eat. That does not make it a longevity intervention. What we have is a plausible adherence tool, a small OMAD study, and larger time-restricted eating trials that keep pointing back to the same unglamorous variable: total energy intake.
What OMAD is, and what it is not
OMAD is the most compressed version of time-restricted eating: one meal, usually within a window of one to two hours, followed by roughly 22 or 23 hours without energy intake. In practice, it is not one protocol. Some people eat a large evening meal. Others place the meal at lunch. Some count calories; many do not. That heterogeneity matters, because meal timing, meal size, protein distribution, alcohol, sleep, medication use, and training all change the physiological result.
The wellness version often starts with mechanism. Long fasting periods change insulin exposure, liver glycogen, fatty-acid use, ketone production, and cellular stress signalling. Those mechanisms are real. The question is whether they translate into better clinical outcomes in free-living adults. On that point, the evidence is thinner than the confidence around the practice suggests.
The best way to think about OMAD is as a constraint. It may help some adults eat less without tracking every meal. It may be too socially, metabolically, or psychologically costly for others. The constraint is not the same as proof of added benefit.
The direct OMAD evidence is small
The most relevant human trial is modest. In a 2022 randomised crossover study of one evening meal per day, lean adults ate either three meals or one evening meal under intended weight-maintenance conditions. The one-meal condition lowered body weight and shifted fuel use during exercise toward greater fat oxidation, whilst measured physical performance was not impaired.
That is interesting, but it is not a long-term health-outcomes trial. The participants were lean, the intervention was short, and the meal was placed in the evening. It does not tell us whether OMAD improves cardiovascular events, diabetes progression, frailty, cancer risk, or lifespan. It also does not tell us whether an older adult trying to preserve muscle should concentrate protein into one sitting.
There is a tendency to treat a shift in substrate use as a proxy for better health. That is a category error. Burning more fat during a test does not automatically mean lower disease risk. It may simply show that the body has adapted to a long daily fast.
Time-restricted eating trials are more informative
Because OMAD-specific trials are sparse, the broader time-restricted eating literature gives the better guardrails. The results are mixed, and that mix is useful. In the TREAT randomised clinical trial in JAMA Internal Medicine, adults with overweight or obesity assigned to a 16:8 pattern did not lose meaningfully more weight or improve cardiometabolic markers more than those eating throughout the day. One concern in that trial was lean-mass loss in the time-restricted group, although the study was not designed around protein timing or resistance training.
In a 2022 New England Journal of Medicine trial, 139 adults with obesity followed calorie restriction with or without an 8 a.m. to 4 p.m. eating window for 12 months. Adding the time window was not more effective for weight, body fat, or metabolic risk factors than calorie restriction alone. That finding does not make time restriction useless. It suggests that, when calories are already controlled, the timing rule may not add much.
Other trials of earlier eating windows have found benefits for weight or blood pressure in selected groups. That does not rescue OMAD as a universal prescription. If anything, it points to a more precise hypothesis: eating earlier and consistently may be different from saving all calories for a large evening meal.
The likely benefit is calorie reduction
Most people do not need a molecular explanation for why OMAD can reduce weight. One meal removes breakfast, lunch, snacks, and late-night grazing. It narrows decision points. For some adults, that is easier than negotiating appetite all day. The clinical question is whether the person can meet nutritional needs inside that window without compensating, bingeing, or under-eating protein and fibre.
This is where the practice becomes less elegant. A single meal that is large enough to meet energy needs can be uncomfortable. A single meal that is comfortable may be too small. For someone with obesity and preserved lean mass, that deficit may be acceptable for a time. For someone older, already lean, highly active, pregnant, recovering from illness, or managing diabetes medication, the same deficit can be a problem.
Protein distribution is a practical concern, not a bodybuilding detail. Muscle protein synthesis responds to per-meal protein dose, and older adults often need more deliberate protein planning. OMAD can make that planning awkward. It is possible to eat enough protein in one meal; it is not always pleasant or repeatable.
Glucose and lipids depend on context
Long fasting lowers the number of post-meal glucose excursions because there is only one post-meal period. The size of that excursion may be larger. A large evening meal can combine high carbohydrate load with a time of day when glucose tolerance is often less favourable than earlier in the day. That makes individual response important, especially for people with prediabetes or type 2 diabetes.
Lipids are similarly context-dependent. Weight loss can improve triglycerides, liver fat, and insulin resistance. A very large meal high in saturated fat or alcohol is a different exposure from a balanced meal built around protein, legumes, vegetables, whole grains, and unsaturated fats. OMAD is a schedule, not a diet quality marker.
There is also the longer-term safety question. the British Heart Foundation’s analysis of a 2024 American Heart Association conference abstract noted an association between eating within a short window and cardiovascular mortality, whilst stressing that the study could not prove cause and effect. That is the correct posture: neither panic nor dismissal. Observational signals should not be treated as verdicts, but they should make us less casual about extreme daily fasting as a permanent habit.
Who should be cautious
OMAD is a poor fit for many people. Anyone using insulin, sulfonylureas, blood-pressure medicines, or medications that require food should discuss fasting with a clinician first. So should people with a history of eating disorders, active cancer treatment, pregnancy, breastfeeding, chronic kidney disease, frailty, or recent unintended weight loss.
Exercise is another constraint. Some people train well fasted; others lose intensity, accumulate fatigue, or compress food so much after training that recovery suffers. The trial evidence does not justify telling athletes, older lifters, or people rebuilding strength that one meal is metabolically superior. The better question is whether the schedule supports the work they are asking their body to do.
Sleep can also move in either direction. Some people sleep better without late snacking. Others sleep worse after a very large evening meal or from hunger in the early morning. A diet that looks elegant on paper but damages sleep is not a longevity strategy.
What this means in practice
- Treat OMAD as an adherence experiment, not a proven anti-ageing intervention.
- If you try it, run a defined trial of two to four weeks rather than making it an identity.
- Keep the meal nutrient-dense: protein, high-fibre carbohydrates, vegetables, unsaturated fats, and enough total energy.
- Avoid placing a very large meal late at night if it worsens reflux, glucose readings, or sleep.
- Track practical outcomes: weight trend, hunger, training, mood, sleep, bowel habits, and medication symptoms.
- Stop or loosen the window if it triggers bingeing, dizziness, menstrual disruption, poor recovery, or obsessive food rules.
What we do not know
We do not know whether OMAD improves long-term cardiovascular outcomes, dementia risk, cancer risk, or lifespan in humans. We do not know the best meal timing, the safest duration, or whether the benefits differ meaningfully by sex, age, diabetes status, training load, or baseline diet quality. We also do not know whether any cellular-stress signalling from a daily 23-hour fast adds benefit once calories, protein, fibre, sleep, exercise, and body weight are accounted for.
That uncertainty should change the recommendation. For most adults, a 10- to 12-hour eating window, earlier dinners, fewer ultra-processed snacks, and adequate protein are less dramatic and better supported than OMAD. For a smaller group, one meal a day may be a workable short-term structure. The evidence supports that narrower claim. It does not support the larger one.
OMAD is not nonsense, and it is not magic. It is a blunt behavioural tool whose main measurable effect is likely to be eating less. If that tool fits your life and biology, it may help. If it does not, the science gives you no reason to force it.
Photo: Annie Trevaskis on Unsplash.